Calando Pharmaceuticals
Calando's RONDEL delivery system extends the reach of RNAi therapy by answering the new field’s most pressing need — an effective and safe systemic delivery method.
CALAA-01, a formulation targeting cancer, combines Calando's proprietary drug delivery system, RONDEL, with an siRNA developed by Calando. CALAA-01 is currently undergoing a Phase 1 clinical trial at UCLA Medical Center in Los Angeles, California and START in San Antonio, Texas.
Our Current Focus
As of now, our team's primary focus is hormone research. We are expecially interested in HGH and HCG hormones reasearch with relation to sports medicine and healthy lifestyle.
We think that thanks to this combined effort the solution we provide for potential customers will shift the edge in this area.
News
- 03/30/16
AHRQ Research Conference Addresses Challenges in Improving Health Care Read - 06/21/15
Health-research sector small businesses invited to learn about NIH funding at national conference Read - 04/12/15
Health-research sector small businesses invited to learn about NIH funding at national conference Read - 03/23/15
Profiles of diverse health research at the University's medical school Read - Read More
Proud supporters of Agency for Healthcare Research & Quality.